{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:10:08Z","timestamp":1777590608225,"version":"3.51.4"},"reference-count":49,"publisher":"Tottori University Faculty of Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Yonago Acta Med."],"published-print":{"date-parts":[[2018]]},"DOI":"10.33160\/yam.2018.06.004","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T22:45:21Z","timestamp":1552603521000},"page":"117-127","source":"Crossref","is-referenced-by-count":5,"title":["The Utility of the Combined Use of &lt;sup&gt;123&lt;\/sup&gt;I-FP-CIT and &lt;sup&gt;123&lt;\/sup&gt;I-MIBG Myocardial Scintigraphy in Differentiating Parkinson\u2019s Disease from Other Parkinsonian Syndromes"],"prefix":"10.33160","volume":"61","author":[{"given":"Eiji","family":"Matsusue","sequence":"first","affiliation":[{"name":"*Department of Radiology, Tottori Prefectural Central Hospital, Tottori 680-0901, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Fujihara","sequence":"additional","affiliation":[{"name":"*Department of Radiology, Tottori Prefectural Central Hospital, Tottori 680-0901, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"\u2020Department of Neurology, Tottori Prefectural Central Hospital, Tottori 680-0901, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Aozasa","sequence":"additional","affiliation":[{"name":"\u2020Department of Neurology, Tottori Prefectural Central Hospital, Tottori 680-0901, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Shimoda","sequence":"additional","affiliation":[{"name":"\u2020Department of Neurology, Tottori Prefectural Central Hospital, Tottori 680-0901, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Nakayasu","sequence":"additional","affiliation":[{"name":"\u2020Department of Neurology, Tottori Prefectural Central Hospital, Tottori 680-0901, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Nakamura","sequence":"additional","affiliation":[{"name":"*Department of Radiology, Tottori Prefectural Central Hospital, Tottori 680-0901, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihide","family":"Ogawa","sequence":"additional","affiliation":[{"name":"\u2021Division of Radiology, Department of Pathophysiological Therapeutic Science, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18656","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Nikolaus S, Antke C, Kley K, Poeppel TD, Hautzel H, Schmidt D, et al.Investigating the dopaminergic synapse in vivo. I. Molecular imaging studies in humans. Rev Neurosci. 2007;18:439-72. PMID: 18330212","DOI":"10.1515\/REVNEURO.2007.18.6.439"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Nikolaus S, Antke C, M\u00fcller HW.In vivo imaging of synaptic function in the central nervous system: I. Movement disorders and dementia. Behav Brain Res. 2009;204:1-31. PMID: 19523495","DOI":"10.1016\/j.bbr.2009.06.008"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 la Foug\u00e8re C, P\u00f6pperl G, Levin J, W\u00e4ngler B, B\u00f6ning G, Uebleis C, et al.The value of the dopamine D2\/3 receptor ligand 18F-desmethoxyfallypride for the differentiation of idiopathic and nonidiopathic parkinsonian syndromes. J Nucl Med. 2010;51:581-7. PMID: 20237026","DOI":"10.2967\/jnumed.109.071811"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 K\u00e4gi G, Bhatia KP, Tolosa E.The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry. 2010;81:5-12. PMID: 20019219","DOI":"10.1136\/jnnp.2008.157370"},{"key":"5","unstructured":"5 Wieland DM, Brown LE, Rogers WL, Worthington KC, Wu JL, Clinthorne NH, et al.Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med. 1981;22:22-31. PMID: 7452352"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Bajaj N, Hauser RA, Grachev ID.Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2013;84:1288-95. PMID: 23486993","DOI":"10.1136\/jnnp-2012-304436"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Pirker W, Asenbaum S, Bencsits G, Prayer D, Gerschlager W, Deecke L, et al.[123I] beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord. 2000;15:1158-67. PMID: 11104200","DOI":"10.1002\/1531-8257(200011)15:6<1158::AID-MDS1015>3.0.CO;2-0"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T, Weiner WJ.Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:976-82. PMID: 16606908","DOI":"10.1212\/01.wnl.0000206363.57955.1b"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Druschky A, Hilz MJ, Platsch G, Radespiel-Tr\u00f6ger M, Druschky K, Kuwert T, et al.Differentiation of Parkinson\u2019s disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J Neurol Sci. 2000;175:3-12. PMID: 10785250","DOI":"10.1016\/S0022-510X(00)00279-3"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Spiegel J, Hellwig D, Farmakis G, Jost WH, Samnick S, Fassbender K, et al.Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson\u2019s disease. Mov Disord. 2007;22:1004-8. PMID: 17427942","DOI":"10.1002\/mds.21499"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Rascol O, Schelosky L.123I-metaiodobenzylguanidine scintigraphy in Parkinson\u2019s disease and related disorders. Mov Disord. 2009;24 Suppl 2:S732-41. PMID: 19877202","DOI":"10.1002\/mds.22499"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Orimo S, Suzuki M, Inaba A, Mizusawa H.123I-MIBG myocardial scintigraphy for differentiating Parkinson\u2019s disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2012;18:494-500. PMID: 22321865","DOI":"10.1016\/j.parkreldis.2012.01.009"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Spiegel J, M\u00f6llers MO, Jost WH, Fuss G, Samnick S, Dillmann U, et al.FP-CIT and MIBG scintigraphy in early Parkinson\u2019s disease. Mov Disord. 2005;20:552-61. PMID: 15645531","DOI":"10.1002\/mds.20369"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Novellino F, Arabia G, Bagnato A, Cascini GL, Salsone M, Nicoletti G, et al.Combined use of DAT-SPECT and cardiac MIBG scintigraphy in mixed tremors. Mov Disord. 2009;24:2242-8. PMID: 19795467","DOI":"10.1002\/mds.22771"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Kim JS, Oh YS, Kim YI, Yang DW, Chung YA, You IeR, et al.Combined use of \u00b9\u00b2\u00b3I-metaiodobenzylguanidine (MIBG) scintigraphy and dopamine transporter (DAT) positron emission tomography (PET) predicts prognosis in drug-induced Parkinsonism (DIP): a 2-year follow-up study. Arch Gerontol Geriatr. 2013;56:124-8. PMID: 22633343","DOI":"10.1016\/j.archger.2012.05.001"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Nuvoli S, Spanu A, Piras MR, Nieddu A, Mulas A, Rocchitta G, et al.123I-ioflupane brain SPECT and 123I-MIBG cardiac planar scintigraphy combined use in uncertain parkinsonian disorders. Medicine (Baltimore). 2017;96:e6967. PMID: 28538394","DOI":"10.1097\/MD.0000000000006967"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Treglia G, Cason E, Cortelli P, Gabellini A, Liguori R, Bagnato A, et al.Iodine-123 metaiodobenzylguanidine scintigraphy and iodine-123 ioflupane single photon emission computed tomography in Lewy body diseases: complementary or alternative techniques?. J Neuroimaging. 2014;24:149-54. PMID: 23163913","DOI":"10.1111\/j.1552-6569.2012.00774.x"},{"key":"18","unstructured":"18 Camacho V, Marqui\u00e9 M, Lle\u00f3 A, Alv\u00e9s L, Artigas C, Flotats A, et al.Cardiac sympathetic impairment parallels nigrostriatal degeneration in Probable Dementia with Lewy Bodies. Q J Nucl Med Mol Imaging. 2011;55:476-83. PMID: 21150861"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Shimizu S, Namioka N, Hirose D, Kanetaka H, Hirao K, Hatanaka H, et al.Comparison of diagnostic utility of semi-quantitative analysis for DAT-SPECT for distinguishing DLB from AD. J Neurol Sci. 2017;377:50-4. PMID: 28477707","DOI":"10.1016\/j.jns.2017.03.040"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Yoshii F, Ryo M, Baba Y, Koide T, Hashimoto J.Combined use of dopamine transporter imaging (DAT-SPECT) and 123I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy for diagnosing Parkinson\u2019s disease. J Neurol Sci. 2017;375:80-5. PMID: 28320195","DOI":"10.1016\/j.jns.2017.01.042"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Uyama N, Otsuka H, Shinya T, Otomi Y, Harada M, Sako W, et al.The utility of the combination of a SPECT study with [123I]-FP-CIT of dopamine transporters and [123I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes. Nucl Med Commun. 2017;38:487-92. PMID: 28410288","DOI":"10.1097\/MNM.0000000000000674"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 S\u00fcdmeyer M, Antke C, Zizek T, Beu M, Nikolaus S, Wojtecki L, et al.Diagnostic accuracy of combined FP-CIT, IBZM, and MIBG scintigraphy in the differential diagnosis of degenerative parkinsonism: a multidimensional statistical approach. J Nucl Med. 2011;52:733-40. PMID: 21498527","DOI":"10.2967\/jnumed.110.086959"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Niimi Y, Ito S, Murate K, Hirota S, Hikichi C, Ishikawa T, et al.Usefulness of combining 123I-FP-CIT-SPECT striatal asymmetry index and cardiac 123I-metaiodobenzylguanidine scintigraphy examinations for diagnosis of parkinsonisms. J Neurol Sci. 2017;377:174-8. PMID: 28477690","DOI":"10.1016\/j.jns.2017.04.026"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Matsusue E, Fink JR, Rockhill JK, Ogawa T, Maravilla KR.Distinction between glioma progression and post-radiation change by combined physiologic MR imaging. Neuroradiology. 2010;52:297-306. PMID: 19834699","DOI":"10.1007\/s00234-009-0613-9"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Matsusue E, Fujihara Y, Tanaka K, Aozasa Y, Shimoda M, Nakayasu H, et al.The utility of the combined use of 123I-FP-CIT SPECT and neuromelanin MR imaging in differentiating Parkinson disease from other parkinsonian syndromes. Acta Radiologica. Forthcoming 2018.","DOI":"10.1177\/0284185118778871"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Hoehn MM, Yahr MD.Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427-42. PMID: 6067254","DOI":"10.1212\/WNL.17.5.427"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al.Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71:670-6. PMID: 18725592","DOI":"10.1212\/01.wnl.0000324625.00404.15"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Litvan I, Agid Y, Calne D, Dubois B, Duvoisin RC, Goetz CG, et al.Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47:1-9. PMID: 8710059","DOI":"10.1212\/WNL.47.1.1"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, et al.Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80:496-503. PMID: 23359374","DOI":"10.1212\/WNL.0b013e31827f0fd1"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Booij J, Kemp P.Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging. 2008;35:424-38. PMID: 17968545","DOI":"10.1007\/s00259-007-0621-0"},{"key":"31","unstructured":"31 Stefanelli A, Treglia G, Bruno I, Rufini V, Giordano A.Pharmacological interference with 123I-metaiodobenzylguanidine: a limitation to developing cardiac innervation imaging in clinical practice?. Eur Rev Med Pharmacol Sci. 2013;17:1326-33. PMID: 23740445"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Tossici-Bolt L, Hoffmann SM, Kemp PM, Mehta RL, Fleming JS.Quantification of 123I-FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio. Eur J Nucl Med Mol Imaging. 2006;33:1491-9. PMID: 16858570","DOI":"10.1007\/s00259-006-0155-x"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Kanda YInvestigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452-8. PMID: 23208313","DOI":"10.1038\/bmt.2012.244"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Brigo F, Matinella A, Erro R, Tinazzi M.\u00b9\u00b2\u00b3I-FP-CIT SPECT (DaTSCAN) may be a useful tool to differentiate between Parkinson\u2019s disease and vascular or drug-induced parkinsonisms: a meta-analysis. Eur J Neurol. 2014;21:1369-e90. PMID: 24779862","DOI":"10.1111\/ene.12444"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Varrone A, Marek KL, Jennings D, Innis RB, Seibyl JP.123I-beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson\u2019s disease and multiple system atrophy. Mov Disord. 2001;16:1023-32. PMID: 11748733","DOI":"10.1002\/mds.1256"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Rossi C, Frosini D, Volterrani D, De Feo P, Unti E, Nicoletti V, et al.Differences in nigro-striatal impairment in clinical variants of early Parkinson\u2019s disease: evidence from a FP-CIT SPECT study. Eur J Neurol. 2010;17:626-30. PMID: 20050904","DOI":"10.1111\/j.1468-1331.2009.02898.x"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Contrafatto D, Mostile G, Nicoletti A, Dibilio V, Raciti L, Lanzafame S, et al.123I-FP-CIT-SPECT asymmetry index to differentiate Parkinson\u2019s disease from vascular parkinsonism. Acta Neurol Scand. 2012;126:12-6. PMID: 21916850","DOI":"10.1111\/j.1600-0404.2011.01583.x"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Tolosa E, Coelho M, Gallardo M.DAT imaging in drug-induced and psychogenic parkinsonism. Mov Disord. 2003;18 Suppl 7:S28-33. PMID: 14531043","DOI":"10.1002\/mds.10575"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Tinazzi M, Antonini A, Bovi T, Pasquin I, Steinmayr M, Moretto G, et al.Clinical and 123I-FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism. J Neurol. 2009;256:910-5. PMID: 19252795","DOI":"10.1007\/s00415-009-5039-0"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Ben\u00edtez-Rivero S, Lama MJ, Huertas-Fern\u00e1ndez I, Alvarez de Toledo P, C\u00e1ceres-Redondo MT, Mart\u00edn-Rodr\u00edguez JF, et al.Clinical features and neuropsychological profile in vascular parkinsonism. J Neurol Sci. 2014 15;345:193-7. PMID: 25108818","DOI":"10.1016\/j.jns.2014.07.046"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Chung EJ, Kim SJ.(123)I-Metaiodobenzylguanidine Myocardial Scintigraphy in Lewy Body-Related Disorders: A Literature Review. J Mov Disord. 2015;8:55-66. PMID: 26090077","DOI":"10.14802\/jmd.15015"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Yoshita MDifferentiation of idiopathic Parkinson\u2019s disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci. 1998;155:60-7. PMID: 9562324","DOI":"10.1016\/S0022-510X(97)00278-5"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y.Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2005;76:249-51. PMID: 15654042","DOI":"10.1136\/jnnp.2004.037028"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Chung EJ, Lee WY, Yoon WT, Kim BJ, Lee GH.MIBG scintigraphy for differentiating Parkinson\u2019s disease with autonomic dysfunction from Parkinsonism-predominant multiple system atrophy. Mov Disord. 2009;24:1650-5. PMID: 19514077","DOI":"10.1002\/mds.22649"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Kim JS, Lee PH, Lee KS, Park JW, Kim YI, Chung YA, et al.Cardiac [123I] metaiodobenzylguanidine scintigraphy for vascular Parkinsonism. Mov Disord. 2006;21:1990-4. PMID: 16991157","DOI":"10.1002\/mds.21112"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Fr\u00f6hlich I, Pilloy W, Vaillant M, Diederich NJ.Myocardial MIBG scintigraphy: a useful clinical tool?: A retrospective study in 50 parkinsonian patients. Neurol Sci. 2010;31:403-6. PMID: 20155379","DOI":"10.1007\/s10072-010-0218-4"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 K\u00f6llensperger M, Seppi K, Liener C, Boesch S, Heute D, Mair KJ, et al.Diffusion weighted imaging best discriminates PD from MSA-P: A comparison with tilt table testing and heart MIBG scintigraphy. Mov Disord. 2007;22:1771-6. PMID: 17579357","DOI":"10.1002\/mds.21614"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Ishibashi K, Saito Y, Murayama S, Kanemaru K, Oda K, Ishiwata K, et al.Validation of cardiac (123)I-MIBG scintigraphy in patients with Parkinson\u2019s disease who were diagnosed with dopamine PET. Eur J Nucl Med Mol Imaging. 2010;37:3-11. PMID: 19626324","DOI":"10.1007\/s00259-009-1202-1"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al.MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord. 2015;30:1591-601. PMID: 26474316","DOI":"10.1002\/mds.26424"}],"container-title":["Yonago Acta Medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yam\/61\/2\/61_2018.06.004\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T15:45:58Z","timestamp":1574351158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yam\/61\/2\/61_2018.06.004\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.33160\/yam.2018.06.004","relation":{},"ISSN":["1346-8049"],"issn-type":[{"value":"1346-8049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}